Regarding the inflammatory parameters analyzed in our studies, 15d-PGJ2 administration inhibits MMP-9, iNOS and COX-2 expression, MPO activity and MDA accumulation in inflammation-related pathologies such as restraint stress exposure, cerebral ischaemia, and colonic inflammation and dysfunction [24,50,51]. This evidence concerns the gene MPO and colitis.